These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 26523776)

  • 1. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.
    Valentijn LJ; Koster J; Zwijnenburg DA; Hasselt NE; van Sluis P; Volckmann R; van Noesel MM; George RE; Tytgat GA; Molenaar JJ; Versteeg R
    Nat Genet; 2015 Dec; 47(12):1411-4. PubMed ID: 26523776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
    Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
    Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
    J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere maintenance is pivotal for high-risk neuroblastoma.
    Hertwig F; Peifer M; Fischer M
    Cell Cycle; 2016; 15(3):311-2. PubMed ID: 26653081
    [No Abstract]   [Full Text] [Related]  

  • 5. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
    Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
    BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
    Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
    Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promotor region rearrangements analyzed in high-risk neuroblastomas by FISH method and whole genome sequencing.
    Kawashima M; Ueda Y; Kurihara S; Hiyama E
    Int J Clin Oncol; 2020 Dec; 25(12):2166-2174. PubMed ID: 32894394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.
    Maris JM
    Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200
    [No Abstract]   [Full Text] [Related]  

  • 11. The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres.
    Graham MK; Xu B; Davis C; Meeker AK; Heaphy CM; Yegnasubramanian S; Dyer MA; Zeineldin M
    Cancer Res Commun; 2024 Jun; 4(6):1533-1547. PubMed ID: 38837897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas.
    Lundberg G; Sehic D; Länsberg JK; Øra I; Frigyesi A; Castel V; Navarro S; Piqueras M; Martinsson T; Noguera R; Gisselsson D
    Genes Chromosomes Cancer; 2011 Apr; 50(4):250-62. PubMed ID: 21319260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
    Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
    Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
    Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
    Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
    Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
    Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.